-AMENDMENTS TO THE CLAIMS-

Please amend the claims as follows:

1-21. (Cancelled)

22. (Previously presented) A method of treating a diabetic complication in a mammal comprising administering to said mammal in need of such treatment

(a) an amount of a first compound, said first compound being a GABA agonist or a pharmaceutically acceptable salt of said GABA agonist; and

(b) an amount of a second compound, said second compound being an aldose reductase inhibitor or a pharmaceutically acceptable salt of said ARI

wherein said first compound and said second compound are each optionally and independently administered together with a pharmaceutically acceptable vehicle, carrier or diluent.

23. (Previously presented) A method of claim 22 wherein said GABA agonist is muscimol, progabide, riluzole, baclofen, gabapentin, vigabatrin, valproic acid, tiagabine, lamotrigine, pregabalin, phenytoin, carbamazepine, topiramate or a pharmaceutically acceptable salt of said GABA agonist.

24. (Previously presented) A method of claim 23 wherein said GABA agonist is gabapentin, tiagabine, lamotrigine, phenytoin, carbamazepine, topiramate, pregabalin or a pharmaceutically acceptable salt of said GABA agonist.

25. (Previously presented) A method of claim 24 wherein said GABA agonist is pregabalin or a pharmaceutically acceptable salt thereof.

26. (Previously presented) A method of claim 24 wherein said GABA agonist is gabapentin or a pharmaceutically acceptable salt thereof.

27. (Previously presented) A method of claim 22 wherein said aldose reductase inhibitor is fidarestat, epalrestat, minalrestat, SPR-210, zenarestat, zopolrestat or a pharmaceutically acceptable salt of said aldose reductase inhibitor.

28. (Previously presented) A method of claim 22 wherein said diabetic complication is diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, diabetic microangiopathy, diabetic macroangiopathy, cataracts or foot ulcers.

29. (Previously presented) A method of treating a diabetic complication in a mammal comprising administering to said mammal in need of such treatment a pharmaceutical composition comprising

(a) an amount of a first compound, said first compound being a GABA agonist or a pharmaceutically acceptable salt of said GABA agonist; and

(b) an amount of a second compound, said second compound being an aldose reductase inhibitor or a pharmaceutically acceptable salt of said ARI.

30. (Previously presented) A method of claim 29 wherein said pharmaceutical composition additionally comprises a pharmaceutically acceptable vehicle, carrier or diluent.

31. (Previously presented) A method of claim 29 wherein said diabetic complication is diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, diabetic microangiopathy, diabetic macroangiopathy, cataracts or foot ulcers.

32. (Currently amended) A pharmaceutical composition comprising:

a. an amount of a GABA agonist[[, a prodrug thereof]] or a pharmaceutically acceptable salt of said GABA agonist ~~or said prodrug~~; and

b. an amount of an ARI[[, a prodrug thereof]] or a pharmaceutically acceptable salt of said ARI [[or said prodrug]].

33. (Previously presented) A pharmaceutical composition of claim 32 additionally comprising a pharmaceutically acceptable vehicle, carrier or diluent.

34. (Currently amended) A pharmaceutical composition of claim 33 wherein said GABA agonist is muscimol, progabide, riluzole, baclofen, gabapentin, vigabatrin, valproic acid, tiagabine, lamotrigine, pregabalin, phenytoin, carbamazepine, topiramate, ~~a prodrug thereof~~ or a pharmaceutically acceptable salt of said GABA agonist ~~or said prodrug~~.

35. (Currently amended) A pharmaceutical composition of claim 34 wherein said GABA agonist is gabapentin, tiagabine, lamotrigine, phenytoin, carbamazepine, topiramate, pregabalin, ~~a prodrug thereof~~ or a pharmaceutically acceptable salt of said GABA agonist ~~or said prodrug~~.

36. (Currently amended) A pharmaceutical composition of claim 35 wherein said GABA agonist is pregabalin[[, a prodrug thereof]] or a pharmaceutically acceptable salt of said pregabalin ~~or said prodrug~~.

37. (Currently amended) A pharmaceutical composition of claim 35 wherein said GABA agonist is gabapentin[[, a prodrug thereof]] or a pharmaceutically acceptable salt of said gabapentin ~~or said prodrug~~.

38. (Currently amended) A pharmaceutical composition of claim 33 wherein said ARI is fidarestat, epalrestat, minalrestat, SPR-210, ~~zenarastat~~ zenarestat, zopolr stat, a ~~prodrug thereof~~ or a pharmaceutically acceptable salt of said ARI ~~or of said prodrug~~.

39. (Currently amended) A pharmaceutical composition of claim 38 wherein said GABA agonist is muscimol, progabide, riluzole, baclofen, gabapentin, vigabatrin, valproic acid, tiagabine, lamotrigine, pregabalin, phenytoin, carbamazepine, topiramate, ~~a prodrug thereof~~ or a pharmaceutically acceptable salt of said GABA agonist ~~or said prodrug~~.

40. (Currently amended) A pharmaceutical composition of claim 39 wherein said GABA agonist is gabapentin, tiagabine, lamotrigine, phenytoin, carbamazepine, topiramate and pregabalin, ~~a prodrug thereof~~ or a pharmaceutically acceptable salt of said GABA agonist ~~or said prodrug~~.

41. (Currently amended) A pharmaceutical composition of claim 40 wherein said GABA agonist is pregabalin[[, a prodrug thereof]] or a pharmaceutically acceptable salt of said pregabalin ~~or said prodrug~~.

42. (Currently amended) A pharmaceutical composition of claim 40 wherein said GABA agonist is gabapentin[[, a prodrug thereof]] or a pharmaceutically acceptable salt of said gabapentin ~~or said prodrug~~.

43. (Currently amended) A kit for achieving a therapeutic effect in a mammal comprising:

a. an amount of a GABA agonist, ~~a prodrug thereof~~ or a pharmaceutically acceptable salt of said GABA agonist, ~~or said prodrug~~ and a pharmaceutically acceptable vehicle, carrier or diluent in a first unit dosage form;

b. an amount of an ARI, ~~a prodrug thereof~~ or a pharmaceutically acceptable salt of said ARI, ~~or said produrg~~ and a pharmaceutically acceptable vehicle, carrier or diluent in a second unit dosage form; and

c. a container.

44. (Currently Amended) A method for treating a mammal in need of therapeutic treatment comprising administering to said mammal

(a) an amount of a first compound, said first compound being a GABA agonist[[, a prodrug thereof]] or a pharmaceutically acceptable salt of said GABA agonist ~~or said prodrug~~; and

(b) an amount of a second compound, said second compound being an ARI[[, a prodrug thereof]] or a pharmaceutically acceptable salt of said ARI ~~or said prodrug~~; wherein said first compound and said second compound are each optionally and independently administered together with a pharmaceutically acceptable vehicle, carrier or diluent.

45. (Currently amended) A method of claim 44 wherein said GABA agonist is muscimol, progabide, riluzole, baclofen, gabapentin, vigabatrin, valproic acid, tiagabine,

lamotrigine, pregabalin, phenytoin, carbamazepine, topiramate, ~~a prodrug thereof~~ or a pharmaceutically acceptable salt of said GABA agonist ~~or said prodrug~~.

46. (Currently amended) A method of claim 45 wherein said GABA agonist is gabapentin, tiagabine, lamotrigine, phenytoin, carbamazepine, topiramate, pregabalin, ~~a prodrug thereof~~ or a pharmaceutically acceptable salt of said GABA agonist ~~or said prodrug~~.

47. (Currently amended) A method of claim 46 wherein said GABA agonist is pregabalin[[, a prodrug thereof]]or a pharmaceutically acceptable salt of said pregabalin ~~or said prodrug~~.

48. (Currently amended) A method of claim 46 wherein said GABA agonist is gabapentin[[, a prodrug thereof]] or a pharmaceutically acceptable salt of said gabapentin ~~or said prodrug~~.